Introducing DurA Cycle Affinity Resin: A Game-Changer in Large-Scale Biologic Manufacturing
ST. PAUL, Minn. & WALTHAM, Mass. - Ecolab, a leader in solutions for water, hygiene, and energy technologies, and Repligen Corporation, a renowned life sciences company specializing in bioprocessing technology, have jointly unveiled a groundbreaking product in the field of large-scale biologic manufacturing. Today, at the prestigious BIO International Convention (BIO 2024) in San Diego, the companies proudly launched Purolite’s DurA Cycle, a protein A chromatography resin that promises to revolutionize purification processes for the biotechnology industry.
The global demand for biologic drugs and therapies is soaring, driven by the increasing prevalence of chronic diseases and the need for more effective treatments. As a result, there is an urgent need for advanced manufacturing technologies capable of producing these drugs efficiently and at a substantial scale. Addressing this demand, DurA Cycle Affinity Resin has emerged as a game-changer, offering unparalleled advantages for large-scale purification processes.
Traditionally, chromatography resins have been the cornerstone of large-scale protein purification processes due to their specificity and selectivity. However, conventional resins have faced challenges such as limited stability, costly manufacturing processes, and a lack of durability for repetitive cycles, leading to increased production costs and a longer time to market for life-saving therapies.
The introduction of DurA Cycle Affinity Resin addresses these concerns, bringing forth a paradigm shift in large-scale biologic manufacturing. The resin offers exceptional chemical stability, enabling more cycles per column and reducing the frequency of resin replacement. This not only streamlines production processes but also significantly lowers costs, making life-saving therapies more affordable and accessible to patients worldwide.
DurA Cycle Affinity Resin is optimized to the stringent requirements of purification processes, delivering high performance, robustness, and reproducibility. With improved biocompatibility, it ensures a higher product yield, reducing the risk of product loss during purification. Additionally, its unique ligand chemistry provides enhanced selectivity and purity, ensuring the highest quality standards for biologic drugs.
The collaboration between Ecolab’s Purolite resin business and Repligen Corporation signifies a remarkable synergy between leading companies in the field of bioprocessing technology. Their joint commitment towards innovation and sustainability has resulted in the development of DurA Cycle Affinity Resin, a groundbreaking technology that is poised to transform large-scale biologic manufacturing.
As the biotechnology industry continues to evolve, the launch of DurA Cycle Affinity Resin marks a significant milestone. Its unparalleled benefits promise to revolutionize large-scale purification processes, setting new industry standards and accelerating the availability of life-saving therapies for patients worldwide. With its introduction at BIO 2024, this game-changing resin is set to make a resounding impact, solidifying its position as a key catalyst for the future of biologic manufacturing.
Comments